Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis

International Journal of Cardiology

Volumn 125, Issue 1, 2008, Pages 85-93

  Bahk, Thomas J ^a   Daniels, Melvin D ^a   Leon, Juan S ^a   Wang, Kegiang ^a   Engman, David M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Angiotensin; Autoimmunity; Collagen; Myocarditis; Myosin

Indexed keywords

CAPTOPRIL; CARDIAC MYOSIN; LOSARTAN; OVALBUMIN;

ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; BODY WEIGHT; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG MECHANISM; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; MALE; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; CAPTOPRIL; FIBROSIS; LOSARTAN; MALE; MICE; MYOCARDITIS; MYOSINS;

EID: 39749181601     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.04.062     Document Type: Article

References (45)

1. Pisani B., Taylor D.O., and Mason J.W. Inflammatory myocardial diseases and cardiomyopathies. Am J Med 102 (1997) 459-469
2. Jacobson D.L., Gange S.J., Rose N.R., and Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84 (1997) 223-243
3. Feldman A.M., and McNamara D. Myocarditis. N Engl J Med 343 (2000) 1388-1398
4. Kuhl U., and Schultheiss H.P. Treatment of chronic myocarditis with corticosteroids. Eur Heart J 16 Suppl O (1995) 168-172
5. Caforio A.L., and McKenna W.J. Recognition and optimum management of myocarditis. Drugs 52 (1996) 515-525
6. Kirchhoff L.V. Chagas disease. American trypanosomiasis. Infect Dis Clin North Am 7 (1993) 487-502
7. Wenger N.K., Abelmann W.H., and Roberts W.C. In: Hurst J.W., and Schlant R.C. (Eds). Myocarditis in The Heart (1990), McGraw Hill, New York, NY 1256-1277
8. Dec G.W., and DeSanctis R.W. In: Dale D.C., and Federman D.D. (Eds). Cardiomyopathies, Chapter XIV in Scientific American Medicine (1998), Scientific American Inc., New York, NY 1-21
9. Migdalof B.H., Antonaccio M.J., McKinstry D.N., et al. Captopril: pharmacology, metabolism and disposition. Drug Metab Rev 15 (1984) 841-869
10. Godsel L.M., Leon J.S., and Engman D.M. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in experimental myocarditis. Curr Pharm Des 9 (2003) 723-735
11. Plosker G.L., and McTavish D. Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Drugs Aging 7 (1995) 226-253
12. Di Bianco R. Captopril in the treatment of congestive heart failure. Herz 12 Suppl 1 (1987) 27-37
13. Suzuki H., Matsumori A., Matoba Y., et al. Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis. An SH-dependent reduction of its expression and myocardial injury. J Clin Invest 91 (1993) 2727-2733
14. Kanda T., Araki M., Nakano M., et al. Chronic effect of losartan in a murine model of dilated cardiomyopathy: comparison with captopril. J Pharmacol Exp Ther 273 (1995) 955-958
15. Araki M., Kanda T., Imai S., Suzuki T., Murata K., and Kobayashi I. Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus. J Cardiovasc Pharmacol 26 (1995) 61-65
16. Takada H., Kishimoto C., Hiraoka Y., Kurokawa M., Shiraki K., and Sasayama S. Captopril suppresses interstitial fibrin deposition in coxsackievirus B3 myocarditis. Am J Physiol 272 (1997) H211-H219
17. Rezkalla S., Kloner R.A., Khatib G., and Khatib R. Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis. Circulation 81 (1990) 1039-1046
18. Rezkalla S., Kloner R.A., Khatib G., and Khatib R. Effect of delayed captopril therapy on left ventricular mass and myonecrosis during acute coxsackievirus murine myocarditis. Am Heart J 120 (1990) 1377-1381
19. Leon J.S., Wang K., and Engman D.M. Captopril ameliorates myocarditis in acute experimental Chagas disease. Circulation 107 (2003) 2264-2269
20. Neu N., Rose N.R., Beisel K.W., Herskowitz A., Gurri-Glass G., and Craig S.W. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 139 (1987) 3630-3636
21. Smith S.C., and Allen P.M. Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol 147 (1991) 2141-2147
22. Smith S.C., and Allen P.M. The role of T cells in myosin-induced autoimmune myocarditis. Clin Immunol Immunopathol 68 (1993) 100-106
23. Bachmaier K., Pummerer C., Shahinian A., et al. Induction of autoimmunity in the absence of CD28 costimulation. J Immunol 157 (1996) 1752-1757
24. Neu N., Pummerer C., Rieker T., and Berger P. T cells in cardiac myosin-induced myocarditis. Clin Immunol Immunopathol 68 (1993) 107-110
25. Penninger J.M., Neu N., Timms E., et al. The induction of experimental autoimmune myocarditis in mice lacking CD4 or CD8 molecules. J Exp Med 178 (1993) 1837-1842
26. Malkiel S., Factor S., and Diamond B. Autoimmune myocarditis does not require B cells for antigen presentation. J Immunol 163 (1999) 5265-5268
27. Neu N., Ploier B., and Ofner C. Cardiac myosin-induced myocarditis: heart autoantibodies are not involved in the induction of the disease. J Immunol 145 (1990) 4094-4100
28. Godsel L.M., Leon J.S., Wang K., Fornek J.L., Molteni A., and Engman D.M. Captopril prevents experimental autoimmune myocarditis. J Immunol 171 (2003) 346-352
29. Baba T., Kanda T., and Kobayashi I. Reduction of cardiac endothelin-1 by angiotensin II type 1 receptor antagonist in viral myocarditis of mice. Life Sci 67 (2000) 587-597
30. Tanaka A., Matsumori A., Wang W., and Sasayama S. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation 90 (1994) 2051-2055
31. Gardner P.L., Mbuy G.N., and Knabb M.T. Effects of the angiotensin II receptor antagonist losartan on herpes simplex virus-type 2 infection of cultured vero and cardiac neonatal myocytes. Life Sci 55 (1994) 283-289
32. Nimata M., Kishimoto C., Yuan Z., and Shioji K. Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis. Mol Cell Biochem 259 (2004) 217-222
33. Tachikawa H., Kodama M., Hui L., et al. Angiotensin II type1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis. J Cardiovasc Pharmacol 41 (2003) S105-S110
34. Groff J.L., Harp J.B., and DiGirolamo M. Simplified enzymatic assay of angiotensin-converting enzyme in serum. Clin Chem 39 (1993) 400-404
35. Shiverick K.T., Thomas L.L., and Alpert N.R. Purification of cardiac myosin: application to hypertrophied myocardium. Biochim Biophys Acta 393 (1975) 124-133
36. Leon J.S., Godsel L.M., Wang K., and Engman D.M. Cardiac myosin autoimmunity in acute Chagas heart disease. Infect Immun 69 (2001) 5643-5649
37. Cushman D.W., and Cheung H.S. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 20 (1971) 1637-1648
38. Delfraissy J.F., Galanaud P., Balavoine J.F., Wallon C., and Dormont J. Captopril and immune regulation. Kidney Int 25 (1984) 925-929
39. Tarkowski A., Carlsten H., Herlitz H., and Westberg G. Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease. Agents Actions 31 (1990) 96-101
40. Gavras H., and Gavras I. Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens 9 (1991) 385-392
41. Linz W., Wiemer G., Gohlke P., Unger T., and Scholkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47 (1995) 25-49
42. Tschope C., Gohlke P., Zhu Y.Z., Linz W., Scholkens B., and Unger T. Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins. J Card Fail 3 (1997) 133-148
43. Erdos E.G., and Marcic B.M. Kinins, receptors, kininases and inhibitors-where did they lead us?. Biol Chem 382 (2001) 43-47
44. Fujii M., Wada A., Ohnishi M., et al. Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure. J Cardiovasc Pharmacol 44 (2004) S346-S349
45. de Cavanagh E.M., Fraga C.G., Ferder L., and Inserra F. Enalapril and captopril enhance antioxidant defenses in mouse tissues. Am J Physiol 272 (1997) R514-R518